Home
Industry Sessions
Visit the Booth
Medscape CME Session
Take Home Trial
Abstracts & Oral Presentations 

Oral Presentations

Session 1:
What’s New with CGM Systems?

Saturday, June 6th 1:30-3:00 PM CT
La Nouvelle Orleans C (Level 2)

CGM for Adults with Type 2 Diabetes Not on Insulin Therapy: The CONNECT Randomized Controlled Trial
1:45 PM | Tom Martens and Roy Beck  

Dexcom Continuous Glucose Monitoring Use and the Risk of Major Adverse Cardiovascular Events in Adults with Type 2 Diabetes
2:00 PM | Jennifer Layne  

Side image

Session 2:
Contemporary and Emerging Diabetes Technologies and Therapies: Psychosocial and Behavioral Considerations

Saturday, June 6th 1:30-3:00 PM CT
La Nouvelle Orleans B (Level 2)

Empowerment Through Visibility: Lived Experiences with CGM vs. Routine Care in Adults with Type 2 Diabetes Not on Insulin 
2:15 PM | Sim Singh

Side image

Session 3:
What’s New with CGM Systems?

Monday, June 8th 3:15-4:15 PM CT
Hall E-2 (Level 1)

Near- and Long-Term Improvements in A1C and CGM Metrics with Dexcom CGM Use in over 7,000 Adults with Type 2 Diabetes 
4:00 PM | Jennifer Layne

Side image

Poster Sessions

All posters located in Poster Hall (Halls D-E) and will be up the entire duration of the conference.
Please note: The dates and times listed indicate when presenters will be at their posters. Posters may be viewed at any time during the conference. 


Saturday, June 6th 12:30-1:30 PM CT 
13-B: New Technology – Glucose Monitoring and Sensing
Continuous Glucose Monitoring Metrics Predict ≥40% eGFR Decline Among Adults With Type 1 and Type 2 Diabetes Presenter: Tomoki Okuno

From Data to Action: Early Real-World Evidence on Behavioral Change and Feature Engagement With Stelo Presenter: Maggie Crawford  

Cost Utility of Real-Time Continuous Glucose Monitoring (RT-CGM) versus Self-Monitoring of Blood Glucose (SMBG) Presenter: Christian Hicks

Reduction in Inpatient Visits and Associated Medical Costs after CGM Initiation among Medicare Advantage (MA) Beneficiaries with T2D Not on Insulin Therapy (NIT) Presenter: Katia Hannah


Sunday, June 7th 12:30-1:30 PM CT
13-B: New Technology – Glucose Monitoring and Sensing
Cost-effectiveness of Dexcom ONE+ Real-time CGM vs. Self-Monitoring of Blood Glucose in People with Insulin-treated Type 2 Diabetes from the Italian Healthcare Payer Perspective Presenter: Jessica Matuoka  

Glycemic Management Before, During, and After Ramadan Fasting in People Living with Diabetes Using Dexcom Continuous Glucose Monitoring: Real-World Data Presenter: Corbin Griffen

Glycemic Profiles of over 136,000 Stelo Users Self-Reporting No Diabetes, Prediabetes, or Type 2 Diabetes Not on Insulin  Presenter: Mingkai Peng

Improvement in Glycemic Outcomes over 6 Months with Stelo Use: Analysis of 12,000 People with Non-Insulin Treated Type 2 Diabetes Presenter: Jennifer Layne

Real-World Use of CGM in Gestational Diabetes Management: A Multi-site Clinical Study Presenter: Amy Valent  


Sunday, June 7th 12:30-1:30 PM CT
11: Psychosocial/Behavioral Medicine 
Increased Confidence and Behavioral Adaptation: Exploring Dexcom CGM Use During Ramadan in People With Diabetes Presenter: Sim Singh


Monday, June 8th 12:30-1:30 PM CT
11: Psychosocial/Behavioral Medicine 
Beyond Glucose: Understanding the Psychosocial and Behavioral Value of Dexcom CGM Among Young Adults With Diabetes Presenter: Christian Hicks

Clinical Evidence

We are excited to bring you new clinical trial data assessing Dexcom CGM across various diabetes types.  Together, with preexisting data, these studies underscore the breadth of evidence behind Dexcom CGM’s role in diabetes care.

Updated glucose management indicator (GMI) better aligns with HbA1c than current GMI:
implications for clinical practice.
Bergenstal, RM, et al. Diabetologia. 2026.

Staging Prediabetes and Type 2 Diabetes: The Time to Start is Now
Shah V, et al. Lancet Diabetes & Endocrinology. 2026;14(1):8-10. 

Initiation of Continuous Glucose Monitoring and Mortality in Type 2 Diabetes 
Reaven PD, et al. Diabetes Tech Thera. 2025;27(10): 778–789.  

Combined Effect of Continuous Glucose Monitoring and Semaglutide: Analysis of Administrative Claims.
Nemlekar P, et al. American J Managed Care. 2025;31(4):183-188. 

Application of continuous glucose monitoring and automated insulin delivery technologies for pregnant women with type 1, type 2, or gestational diabetes: an international consensus statement.
Benhalima K, et al. Lancet Diabetes & Endocrinology. 2026;14(2): 157-177.

Questions?

If you have any questions, please contact Dexcom at events@dexcom.com
*Results with Dexcom CGM have been proven in over 70 clinical studies, data available on clinicaltrials.gov. Dexcom, Dexcom Clarity, Dexcom Follow, Dexcom One, Dexcom Share, Stelo, and any related logos and design marks are either registered trademarks or trademarks of Dexcom, Inc. in the United States and/or other countries.

BRIEF SAFETY STATEMENT: Failure to use the Dexcom Continuous Glucose Monitoring System and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the Dexcom CGM do not match symptoms, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency. 

MAT-13836